Yizhou Huang

Yizhou Huang

Auto-generated profile, based on publicly available information

Yizhou Huang

Children's Cancer Institute Lowy Cancer Research Centre Randwick New South Wales Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Cell
Verified
Journal Article
Closed access
Justin WongJustin Wong
Justin Wong
WRWilliam Ritchie
William Ritchie
OEOlivia A. Ebner
Olivia A. Ebner
MSMatthias Selbach
Matthias Selbach
JWJason W. H. Wong
Jason W. H. Wong
JRJohn E.J. Rasko
John E.J. Rasko

1 July 2017 in Cell Reports
Verified
Journal Article
Open access
AUAshwin Unnikrishnan
Ashwin Unnikrishnan
EPElli Papaemmanuil
Elli Papaemmanuil
DBDominik Beck
Dominik Beck
NDNandan P. Deshpande
Nandan P. Deshpande
AVArjun Verma
Arjun Verma
JPJohn E. Pimanda
John E. Pimanda
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-responders. Here, we show that AZA responders have more hematopoietic progenitor cells (HPCs) in the cell cycle. Non-responder HPC quiescence is mediated by integrin α5 (ITGA5) signaling and their hematopoietic potential improved by combining AZA with an ITGA5 inhibitor. AZA response is associated with the induction of an inflammatory response in HPCs in vivo. By molecular bar coding and tracking individual clones, we found that, although AZA alters the sub-clonal contribution to different lineages, founder clones are not eliminated and continue to drive hematopoiesis even in complete responders.

9 August 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAdrian Schwarzer
Adrian Schwarzer
SEStephan Emmrich
Stephan Emmrich
FSFranziska Schmidt
Franziska Schmidt
DBDominik Beck
Dominik Beck
MNMichelle Ng
Michelle Ng
JKJan-Henning Klusmann
Jan-Henning Klusmann
Non-coding RNAs have emerged as crucial regulators of gene expression and cell fate decisions. However, their expression patterns and regulatory functions during normal and malignant human hematopoiesis are incompletely understood. Here we present a comprehensive resource defining the non-coding RNA landscape of the human hematopoietic system. Based on highly specific non-coding RNA expression portraits per blood cell population, we identify unique fingerprint non-coding RNAs—such as LINC00173 in granulocytes—and assign these to critical regulatory circuits involved in blood homeostasis. Following the incorporation of acute myeloid leukemia samples into the landscape, we further uncover prognostically relevant non-coding RNA stem cell signatures shared between acute myeloid leukemia blasts and healthy hematopoietic stem cells. Our findings highlight the importance of the non-coding transcriptome in the formation and maintenance of the human blood hierarchy.

1 December 2018 in Cancer Cell
Verified
Journal Article
Closed access
DJDuohui Jing
Duohui Jing
YHYizhou Huang
Yizhou Huang
XLXiaoyun Liu
Xiaoyun Liu
KSKeith C.S. Sia
Keith C.S. Sia
JZJulia C. Zhang
Julia C. Zhang
RLRichard Lock
Richard Lock

26 October 2023 in Blood
Verified
Journal Article
Open access
PDF file
SSShruthi Subramanian
Shruthi Subramanian
JTJulie A. I. Thoms
Julie A. I. Thoms
YHYizhou Huang
Yizhou Huang
PCPaola Cornejo-Páramo
Paola Cornejo-Páramo
FKForrest C. Koch
Forrest C. Koch
JPJohn E. Pimanda
John E. Pimanda
Hematopoietic stem and progenitor cells (HSPCs) rely on a complex interplay among transcription factors (TFs) to regulate differentiation into mature blood cells. A heptad of TFs (FLI1, ERG, GATA2, RUNX1, TAL1, LYL1, LMO2) bind regulatory elements in bulk CD34+ HSPCs. However, whether specific heptad-TF combinations have distinct roles in regulating hematopoietic differentiation remains unknown. We mapped genome-wide chromatin contacts (HiC, H3K27ac, HiChIP), chromatin modifications (H3K4me3, H3K27ac, H3K27me3) and 10 TF binding profiles (heptad, PU.1, CTCF, STAG2) in HSPC subsets (stem/multipotent progenitors plus common myeloid, granulocyte macrophage, and megakaryocyte erythrocyte progenitors) and found TF occupancy and enhancer-promoter interactions varied significantly across cell types and were associated with cell-type–specific gene expression. Distinct regulatory elements were enriched with specific heptad-TF combinations, including stem-cell–specific elements with ERG, and myeloid- and erythroid-specific elements with combinations of FLI1, RUNX1, GATA2, TAL1, LYL1, and LMO2. Furthermore, heptad-occupied regions in HSPCs were subsequently bound by lineage-defining TFs, including PU.1 and GATA1, suggesting that heptad factors may prime regulatory elements for use in mature cell types. We also found that enhancers with cell-type–specific heptad occupancy shared a common grammar with respect to TF binding motifs, suggesting that combinatorial binding of TF complexes was at least partially regulated by features encoded in DNA sequence motifs. Taken together, this study comprehensively characterizes the gene regulatory landscape in rare subpopulations of human HSPCs. The accompanying data sets should serve as a valuable resource for understanding adult hematopoiesis and a framework for analyzing aberrant regulatory networks in leukemic cells.

20 August 2020 in Blood
Verified
Journal Article
Open access
PDF file
CCCatherine L. Carmichael
Catherine L. Carmichael
JWJueqiong Wang
Jueqiong Wang
TNThao Nguyen
Thao Nguyen
OKOluseyi Kolawole
Oluseyi Kolawole
ABAissa Benyoucef
Aissa Benyoucef
Jody HaighJody Haigh
Jody Haigh
Modulators of epithelial-to-mesenchymal transition (EMT) have recently emerged as novel players in the field of leukemia biology. The mechanisms by which EMT modulators contribute to leukemia pathogenesis, however, remain to be elucidated. Here we show that overexpression of SNAI1, a key modulator of EMT, is a pathologically relevant event in human acute myeloid leukemia (AML) that contributes to impaired differentiation, enhanced self-renewal, and proliferation of immature myeloid cells. We demonstrate that ectopic expression of Snai1 in hematopoietic cells predisposes mice to AML development. This effect is mediated by interaction with the histone demethylase KDM1A/LSD1. Our data shed new light on the role of SNAI1 in leukemia development and identify a novel mechanism of LSD1 corruption in cancer. This is particularly pertinent given the current interest surrounding the use of LSD1 inhibitors in the treatment of multiple different malignancies, including AML.